S. Ravindran, Rutuja Rokade, J. Suthar, Pooja Singh, Pooja Deshpande, Rajeshree Khambadkar, Srushti Utekar
{"title":"In Vitro Biotransformation in Drug Discovery","authors":"S. Ravindran, Rutuja Rokade, J. Suthar, Pooja Singh, Pooja Deshpande, Rajeshree Khambadkar, Srushti Utekar","doi":"10.5772/INTECHOPEN.73173","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.73173","url":null,"abstract":"In vitro Biotransformation studies play a crucial role in drug discovery program that determine the fate of the new chemical entities (NCE’s). Enzyme rich matrices such as microsomes, hepatocytes, liver fractions and S9 fractions transform the new chemical entities to different metabolites. Metabolites could be pharmacologically important or toxic. Newly formed metabolites are identified using liquid chromatography interfaced with mass spectrometry. Identification of the biotransformation sites in the new chemical entity helps the medicinal chemists to optimize its structure and develop the NCE as a pharmaceutical drug. Screening pharmaceutical drugs using in vitro biotransformation studies assist in selecting the right new chemical entity for further in vivo studies in animal systems and later in human clinical trials.","PeriodicalId":191867,"journal":{"name":"Drug Discovery - Concepts to Market","volume":"43 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121819335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. D. L. Lastra, Cristina Garrido-Orduña, A. A. Borges, David Jíménez-Arias, Francisco J García-Machado, Mercedes Hernández, Concepción C. González, A. Boto
{"title":"Bioinformatics Discovery of Vertebrate Cathelicidins from the Mining of Available Genomes","authors":"J. D. L. Lastra, Cristina Garrido-Orduña, A. A. Borges, David Jíménez-Arias, Francisco J García-Machado, Mercedes Hernández, Concepción C. González, A. Boto","doi":"10.5772/INTECHOPEN.76631","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.76631","url":null,"abstract":"Due to the worrying increase in antimicrobial resistance to conventional antibiotics, the search for alternatives is becoming increasingly important. Antimicrobial peptides (AMPs), originating from natural resources, have been recognised as a novel class of antibiotics. An advantage of peptides over antibiotics is that the resistance is more difficult to attain than for conventional antibiotics. With the increasing number of genomes sequenced and available in the public domain, one alternative methodology to obtain novel AMPs is to analyse genes and proteins from genomic databases to predict and identify amino acid sequences that share similarities and molecular features with natural bioactive antimicrobial peptides. In this chapter, we summarise some of our recent results on the production of antimicrobial peptides, particularly, how we managed to identify a family of antimicrobial peptides: cathelicidins, through bioinformatics tools, from the genomes of two lower vertebrates (a reptile and a bird) available in public databases. We hope that our preliminary investigation with these novel peptides could be useful for the design of future strategies that pursue the production of antimicrobial peptides through biotechnology.","PeriodicalId":191867,"journal":{"name":"Drug Discovery - Concepts to Market","volume":"100 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115741285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Medicinal Plants of West Godavari","authors":"S. Pola, Venkata Narasimha Kadali","doi":"10.5772/INTECHOPEN.73499","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.73499","url":null,"abstract":"Medicinal plants are one of the nature’s greatest gifts to the mankind. Each plant will have an exquisite deal of character, which can act as an antidote to various of diseases. Traditional medicine has become a vital alternative source of medicine all over the world today with some approximation of about 80% of the primary health care system in some developing countries. Medicinal plants are known to comprise of hundreds of active constituents that may be potentially useful for the development of therapeutic agents. The development of therapeutic agents involves the isolation and identifica - tion of bioactive compounds from plant materials which is crucial for drug discovery. Researchers from all around the globe have focused on drug discovery from the natures’ wonder medicinal plants, forming an important group of complementary and alternative medicine (CAM) therapy. West Godavari is a part of Andhra Pradesh, India, which hosts several plants that have high therapeutic significance. Each of the plants has a unique feature which can be employed for healing of various lethal diseases. The present examination intends to review the therapeutic plant assets of West Godavari area Andhra Pradesh. This evaluation also offers the critical elements which include medicinal properties of various medicinal plants found in West Godavari district of Andhra Pradesh, India.","PeriodicalId":191867,"journal":{"name":"Drug Discovery - Concepts to Market","volume":"28 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116662990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Cell-Based Screening to Identify Cytoprotective Compounds","authors":"Domokos Gerő","doi":"10.5772/INTECHOPEN.73172","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.73172","url":null,"abstract":"Prevention of cellular injury and consequent cell death is expected to provide therapeutic benefit in various diseases, but with the complexity of cell damaging pathways involved, identification and validation of novel potential drug targets is not a trivial task. New drug targets are expected to take part in complex responses with wide-ranging effects on gene expression and cellular function and drug candidates rather modify these effects than act as simple agonists or antagonists to ultimately protect the cells from an injury. Phenotypic screening may help identify cytoprotective compounds in diseases, in which the lack of drug targets makes target-based approaches unfeasible. This chapter gives an overview of the strategy of cell-based assay development, primary screening, hit selection and confirmation. Considerations about the choice of small molecule compound libraries utilized in cell-based models are discussed as well as the use of clinical drugs for drug repurposing or repositioning. The choice of cell types and issues associated with cell culture techniques are overviewed and the most common assays and readouts are briefly described. Finally, the potential pitfalls of data analysis and hit selection are discussed.","PeriodicalId":191867,"journal":{"name":"Drug Discovery - Concepts to Market","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126486405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"On the Organization of a Drug Discovery Platform","authors":"J. Boutin, O. Nosjean, G. Ferry","doi":"10.5772/INTECHOPEN.73170","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.73170","url":null,"abstract":"Some of the most exciting parts of work in the pharmaceutical industry are the steps lead- ing up to drug discovery. This process can be oversimplified by describing it as a screen ing campaign involving the systematic testing of many compounds in a test relevant to a given pathology. This naïve description takes place without taking into consideration the numerous key steps that led up to the screening or the steps that might follow. The present chapter describes this whole process as it was conducted in our company during our early drug discovery activities. First, the purpose of the procedures is described and rationalized. Next follows a series of mostly published examples from our own work illustrating the various steps of the process from cloning to biophysics, including expression systems and membrane-bound protein purifications. We believe that what is described here presents an example of how pharmaceutical industry research can orga- nize its platform(s) when the goal is to find and qualify a new preclinical drug candidate using cutting-edge technologies and a lot of hard work.","PeriodicalId":191867,"journal":{"name":"Drug Discovery - Concepts to Market","volume":"28 3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122596306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Biomedical and Pharmaceutical Applications of Inductively Coupled Plasma-Mass Spectrometry (ICP-MS)","authors":"D. N. Reddy, A. J. Al-Rajab, G. Reddy","doi":"10.5772/INTECHOPEN.74787","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.74787","url":null,"abstract":"Medical science is a field of study that is relevant to all people, but the development of pharmaceutical, biomedical and life science is of particular importance. In these fields, further studies are being established to determine with incredible accuracy the quantities and concentration of inorganic elements and organic compounds, such as nucleotides, sulphur and phosphorous containing peptides and proteins, to be used in all kinds of drugs. Since 1980, inductively coupled plasma-mass spectrometry (ICP-MS) has emerged as a new and powerful technique for elemental and isotopic analysis. It provides a means for the analysis of an extremely wide range of elements and the co-analysis of most elements in the periodic table. It can also be used for qualitative, quantitative and semi- quantitative analysis and for the measurement of isotopic ratios through mass-to-charge ratios. In recent years, ICP-MS has emerged as the best technique for the quantification of inorganic impurities in pharmaceutical and biomedical applications. This chapter focuses on introducing the applications of ICP-MS in the pharmaceutical and biomedical fields. Some problems facing ICP-MS are also presented at the end of this chapter.","PeriodicalId":191867,"journal":{"name":"Drug Discovery - Concepts to Market","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129864418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pharmacologic Interventions for Preventing Chondrocyte Apoptosis in Rheumatoid Arthritis and Osteoarthritis","authors":"C. Malemud","doi":"10.5772/INTECHOPEN.73174","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.73174","url":null,"abstract":"Chronic inflammation drives the progression of rheumatoid arthritis (RA) and osteo - arthritis (OA) to synovial joint failure. The inflammatory state in both musculoskeletal diseases is associated with significantly elevated levels of pro-inflammatory cytokines in joint synovial fluid, which is best exemplified by increases in interleukin-1β (IL-1β), IL-6, IL-17, tumor necrosis factor-α, among others, as well as increased activity of soluble mediators such as nitric oxide and certain growth factors including vascular endothe lial growth factor and fibroblast growth factor. The multitude of these factors activate chondrocyte signal transduction pathways resulting in programmed cell death, other wise known as apoptosis as well as compromising chondrocyte autophagy. Importantly, chondrocyte apoptosis causes a loss of articular cartilage vitality which dampens carti lage repair mechanisms because at present, the possibility that chondrocyte progenitor cells could replace those differentiated chondrocytes lost via apoptosis remains debat -able. Certain pharmacologic interventions which have been proven to induce apoptosis in various cancer cell studies in vitro suggest the possibility that drugs could be devel oped to specifically suppress or completely inhibit chondrocyte apoptosis in RA and OA cartilage. This review supports that contention and indicates that apoptosis can be inhibited by identifying novel cellular targets which promote apoptosis and autophagy.","PeriodicalId":191867,"journal":{"name":"Drug Discovery - Concepts to Market","volume":"97 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133192649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Drug Treatment of Obesity: From Bench to Bedside","authors":"J. Jakab, R. Smolić, A. Včev, M. Smolić","doi":"10.5772/INTECHOPEN.73559","DOIUrl":"https://doi.org/10.5772/INTECHOPEN.73559","url":null,"abstract":"Obesity is a complex metabolic and behavioural disorder associated with increased health risk, including coronary artery disease, congestive heart failure and sudden cardiac death. Effective prevention and treatment strategies for obesity are needed. This unmet need for efficient and safe antiobesity medication resulted in many new therapies at various stages of development. Obesity has become one of the most intensively studied diseases because of the availability of suitable animal and cell culture models of adipocyte differentiation and appetite regulation. obstructive and certain types of cancer.","PeriodicalId":191867,"journal":{"name":"Drug Discovery - Concepts to Market","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2018-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115361238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}